← Back to updates
Myelin repairLaboratory cells onlyLaboratory model of myelin repair; no clinical outcome

Peer-reviewed laboratory model using human stem-cell-derived tissue; no patients treated

Human cell spheroids model myelin injury and repair in the laboratory

Published by MyelinWatch:

What happened

A Nature Neuroscience paper published on 1 October 2026 describes three-dimensional spheroids made from human induced pluripotent stem cells. They contain myelinating oligodendrocytes and responsive microglia. After experimentally induced myelin injury, researchers observed debris clearance, generation of new oligodendrocytes and new, thinner myelin sheaths around axons. Remyelination was observed in only about half of differentiations. Developmental maturity is another limitation: stem-cell-derived models may not fully reflect adult tissue. The model can help study repair mechanisms and screen candidate compounds, but a spheroid cannot reproduce all features of adult multiple sclerosis (MS).

What this means for people with MS

This is laboratory research, not a clinical trial or a treatment. No person with MS received an intervention in this study, and the paper does not demonstrate restored myelin or improved disability in patients. Any drug lead from this model would need separate testing.

About the approach studied in this programme: Human iPSC myelin spheroid model

Scientists grow three-dimensional spheres from human stem cells with myelin-making oligodendrocytes and microglia, then deliberately injure their myelin. The model lets them observe debris clearance and formation of new sheaths in a dish; it is a laboratory research tool, not a cell treatment given to people with MS.

Approach source: Nature Neuroscience — original spheroid-model article ↗

What kind of evidence exists?
Original peer-reviewed Nature Neuroscience cell-model study
How reliable is this source?
Original peer-reviewed Nature Neuroscience paper, DOI 10.1038/s41593-026-02457-z, PMID 42823475
Source: Nature Neuroscience — Ramesan et al. — original peer-reviewed research article ↗Source: PubMed — Nature Neuroscience original article PMID 42823475 ↗
Research event/source date
Published by MyelinWatch
Last substantive MyelinWatch update

Related substantive developments

Research event/source date:
Emerging treatments + myelin repairRegistered study in peopleFirst participant dosed; no results posted

Combined early Phase 1/2a study in people; no results posted

PRO-1562: Progentos reports first participant dosed in an early study of a possible myelin-repair drug

Organisation: Progentos Therapeutics · United States

On 3 November 2026, Progentos Therapeutics announced that the first participant has been dosed in its Phase 1/2a study of PRO-1562 (NCT07826689), an experimental oral small molecule designed to repair myelin in multiple sclerosis (MS). The company did not give the dosing date or say in which part of the study this happened. It describes the Phase 1 part as placebo-controlled single rising doses in healthy adults at one site in Australia, so the announcement does not show whether that participant received PRO-1562 or placebo. The later Phase 2a part plans six months of once-monthly doses or placebo in adults with relapsing MS and chronic optic neuropathy. The company says that the drug promoted myelin repair in laboratory and animal studies; it reports no human results. The ClinicalTrials.gov record, last updated on 29 September 2026 and checked on 6 November, still shows the study as accepting participants, an estimated October 2026 start and no posted results.

Published by MyelinWatch:

What this means for people with MS

According to the company, this study has started dosing. That does not show that PRO-1562 is safe, that it repairs myelin in people or that it helps people with MS. Laboratory and animal results may not apply to people. The announcement does not establish that the MS part has opened. PRO-1562 is an experimental drug, not an available treatment. The registry lists one site, in Adelaide, Australia, and none in Greece. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Research event/source date:
Myelin repairResults from peopleNo reported conclusion on effect

Published longitudinal imaging cohort study in people

MRI study follows a myelin-sensitive signal in MS lesions over about one year

Organisation: Second Hospital & Clinical Medical School, Lanzhou University · China

Researchers at the Second Hospital of Lanzhou University, China, used an MRI technique called APART-QSM, which separates a myelin-sensitive (diamagnetic) signal from an iron-sensitive one. At the first scan, white matter lesions had a lower myelin-sensitive signal than the corresponding normal-appearing white matter. In the 101 people with multiple sclerosis who had a second scan after a median of about one year, the myelin-sensitive signal in lesions increased. Larger increases were associated with female sex, ofatumumab treatment, relapsing-remitting MS and improvement in EDSS disability scores, and they were smaller with longer disease duration.

Published by MyelinWatch:

What this means for people with MS

The work tests whether this MRI method could track changes linked to remyelination. It does not show that myelin was restored, that ofatumumab repairs myelin, or that the signal explains changes in disability: this was an observational cohort with no randomised comparison of treatments, and about 30% of the people with MS had no follow-up scan. There is still no established approved treatment in clinical practice proven to reliably restore myelin in MS. It does not support a change to an individual treatment.

Research event/source date:
Myelin repairLaboratory or animal researchLess myelin damage and inflammation in mouse models; not clinical benefit

Mouse experiments; not tested in people

Mouse study links chronic demyelination to a dysfunctional microglial state

Organisation: Technical University of Munich and German Center for Neurodegenerative Diseases (DZNE) · Germany

Researchers at the Technical University of Munich and the German Center for Neurodegenerative Diseases (DZNE) compared mouse models of acute and chronic myelin loss. With chronic demyelination, microglia, the brain's immune cells, entered a distinct state with ongoing inflammation, fats trapped inside their lysosomes and fewer lipid droplets, together with higher cholesterol production and lower cholesterol export. A desmosterol-like compound (DMHCA) reversed this state, reduced inflammatory signalling and myelin damage, and improved movement in a mouse model of the inherited myelin disorder Pelizaeus–Merzbacher disease. In experimental autoimmune encephalomyelitis (EAE), a mouse model used to study MS, DMHCA lessened disease severity and reduced lesions. In post-mortem tissue from chronic active MS lesions of 3 people, about 75% of phagocytic immune cells (CD68+) carried a marker of this inflammatory state (CCL4), compared with about 13% in white matter from people without MS.

Published by MyelinWatch:

What this means for people with MS

The study points to a possible research target for chronic myelin damage, including in MS. The compound was given only to mice, EAE mice do not reproduce all features of MS, and the human finding is a small descriptive tissue observation, so the work cannot show that the compound would be safe or useful for people with multiple sclerosis. There is no established approved treatment in clinical practice proven to reliably restore myelin in MS. It does not support a change to an individual treatment.